Tirzepatide (30mg)

Tirzepatide (LY3298176) is a synthetic 39-amino acid acylated peptide that acts as a dual agonist at both the GIP and GLP-1 incretin receptors. In preclinical and clinical research it has been studied for its effect on glucose-dependent insulin secretion, energy intake and body-weight regulation in metabolic models, and downstream cAMP/PKA signalling at both receptor families. The dual-incretin mechanism distinguishes it from earlier single-receptor (GLP-1 only) research compounds. Supplied at >99% HPLC purity for in-vitro research use only.

No. The Tirzepatide we supply is not a pre-filled pen, injectable device, or commercial pharmaceutical product, and it is not stocked at retail pharmacies such as Chemist Warehouse. Commercial Tirzepatide medicines (e.g. Mounjaro) are prescription-only products regulated by the TGA and dispensed through pharmacies on a doctor's prescription. Peptide Warehouse Australia supplies Tirzepatide exclusively as a lyophilised powder for in-vitro laboratory research purposes — not for human use. If you have seen research Tirzepatide advertised as pens or bulk 100mg quantities elsewhere, exercise caution regarding the source and purity verification.

All three are incretin-pathway research compounds, but they differ in how many receptors they engage. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide is a triple agonist that adds glucagon-receptor activity to GIP and GLP-1. In comparative metabolic research, the number and combination of receptors engaged is a primary variable of interest. They are distinct research tools and are not interchangeable in a protocol. See our blog guide 'Retatrutide vs Tirzepatide vs Semaglutide' for a detailed research comparison. Not for human consumption — for research use only.

Add bacteriostatic water to the vial slowly, directing it down the inside wall rather than onto the powder, then swirl gently until fully dissolved. Do not shake or vortex. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 4 weeks, protected from light. BAC water is available at /products/bac-water-10ml. Not for human consumption — for research use only.

Legal status: Tirzepatide is legal to purchase in Australia for legitimate laboratory research purposes when supplied as a research compound. It is not for human consumption, therapeutic, cosmetic, or veterinary use, and is not TGA-approved in this form. Purchasers must be 18+ and confirm research-only intent. Quality: each batch is manufactured to a >99% HPLC purity specification under GMP-certified conditions.

Peptide Warehouse Australia stocks Tirzepatide 10mg and 30mg and ships nationwide via Australia Post with full tracking. Orders placed before 12PM AEST dispatch the same business day from our Melbourne warehouse; orders after 12PM AEST dispatch the next business day. Standard Post $8.99 (2–6 business days); Express Post $13.99 (1–3 business days); free shipping on all orders over $199 AUD. All orders ship in discreet plain packaging with no external branding. Not for human consumption — for research use only.

Tirzepatide simultaneously engages the GIP and GLP-1 incretin receptors, and research examines how co-activation of both pathways influences glucose-dependent insulin secretion and energy balance compared with single GLP-1 agonism. This dual-incretin mechanism is the defining feature of Tirzepatide research. Not for human consumption — for research use only.

Semaglutide is a single GLP-1 agonist, Tirzepatide is a dual GIP/GLP-1 agonist, and Retatrutide (/products/retatrutide-10mg) is a triple agonist adding glucagon activity. The number of receptors engaged is the primary research variable distinguishing these incretin tools. See our blog comparison for detail. Not for human consumption — for research use only.

Tirzepatide has been examined in large clinical research programmes (named SURPASS and SURMOUNT) studying glycaemic and body-weight endpoints. These are clinical research findings; our Tirzepatide is supplied strictly as a research compound and is not the TGA-approved medicine. Not for human consumption — for research use only.

Tirzepatide is acylated to extend its half-life, supporting once-weekly dosing intervals in clinical research. This long-acting profile is part of why it is studied as a sustained dual-incretin research tool. Working intervals and concentrations are protocol-dependent. Not for human consumption — for research use only.

Working concentration scales with reconstitution volume and vial size. Use our peptide calculator (/tools/peptide-calculator) to plan dilutions for your protocol. We provide no dosing guidance. Not for human consumption — for research use only.

Tirzepatide is often shortened to Tirz and appears in research under the Eli Lilly development code LY3298176. It is a dual GIP and GLP-1 receptor agonist research peptide. For in-vitro research use only.